The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
A Japanese clinical research group has suggested that antiandrogen withdrawal after combined androgen blockade may work best in men whose cancer is progressing rapidly after a long period on an LHRH agonist + antiandrogen therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: advanced, antiandrogen, castration-resistant, withdrawal | Leave a comment »
An article in today’s New England Journal of Medicine discusses treatment-induced gynecomastia (swelling and soreness of the breasts) in men being treated with androgen receptor inhibitors (antiandrogens) for progressive prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, gynecomastia | 4 Comments »
According to a new, systematic review of data from four independently conducted clinical trials, tamoxifen may be the most effective agent for the management of breast events induced by treatment with non-steroidal antiandrogens (e.g., bicalutamide) in men with prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: antiandrogen, breast, gynecomastia, pain, tamoxifen | 7 Comments »
According to a media release issued by Medivation immediately prior to the annual meeting of the American Association for Cancer Research in Chicago (now wrapping up), the drug we have all known as MDV3100 for the past few years now has an approved “scientific” name: enzalutamide. … READ MORE …
Filed under: Drugs in development | Tagged: antiandrogen, enzalutamide, MDV3100 | 1 Comment »
An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, bicalutamide, effect, orientation, sexual | Leave a comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a comment »
While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem of disease “flare” associated with this first injection of the LHRH. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, flare, LHRH agonist, testosterone | 1 Comment »
Today’s important news reports address:
Filed under: Drugs in development, Management, Treatment | Tagged: antiandrogen, apoptosis, approval, arteries, brachytherapy, denosumab, iodine-125, long-term, lymphocyte, radiation therapy, stiffening, survival, toremifene, toxicity | Leave a comment »
Newly published studies today include data on:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, antiandrogen, atypia, bicalutamide, brachytherapy, cancer, depression, fatigue, flutamide, irritability, mood, prostate, quality of life, radiotherapy | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 